Gebasaxturev is under clinical development by Merck & Co and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Gebasaxturev’s likelihood of approval (LoA) and phase transition for Adenocarcinoma Of The Gastroesophageal Junction took place on 09 Nov 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

In addition, the same event on 09 Nov 2022 increased Gebasaxturev’s LoA and PTSR for Gastric Cancer.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Gebasaxturev Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Gebasaxturev overview

Cavatak (Coxsackievirus A21, CVA-21) is under development for the treatment of colorectal cancer, metastatic uveal melanoma, solid tumors, non-muscle invasive bladder cancer, metastatic castrate-resistant prostate cancer, head and neck cancer, triple-negative breast cancer, advanced or metastatic head and neck squamous cell carcinoma, cutaneous squamous cell carcinoma, hepatocellular carcinoma, metastatic gastric cancer, gastroesophageal junction (GEJ) adenocarcinoma, non-small cell lung cancer, chronic lymphocytic leukemia, acute myeloid leukemia, prostate cancer, pancreatic cancer, metastatic melanoma and bladder cancer. It was also under development for the treatment of glioma, mesothelemia, breast cancer,  and multiple myeloma. Coxsackievirus A21 is administered through intratumoral, intravesical and intravenous route. Cavatak is the formulation of the Coxsackievirus Type A21 (CVA21). Coxsackievirus A21 acts via ICAM-1 targeted virotherapy which delays or avoids the impact of virus neutralization. The drug candidate is developed using oncolytic virotherapy technology.

Merck & Co overview

Merck & Co (Merck) is a biopharmaceutical company focused on the discovery, development, manufacturing and marketing of prescription medicines, biologic therapies, vaccines and animal health products. It offers prescription products for therapy areas related to cardiovascular, cancer, immune disorders, infectious, respiratory and women’s diseases, and diabetes. The company provides animal health products such as vaccines, poultry products, livestock products and aquaculture products. Merck sells medicines to drug wholesalers, retailers, hospitals, government agencies and managed health care providers; and animal health products to veterinarians, distributors and animal producers. The company and its subsidiaries operate in the Americas, Europe, the Middle East, Africa, Asia Pacific, and Latin America. Merck is known as MSD outside the US and Canada and is headquartered in Kenilworth, New Jersey, the US.

Quick View Gebasaxturev LOA Data

Report Segments
  • Innovator
Drug Name
  • Gebasaxturev
Administration Pathway
  • Intratumor
  • Intravenous
  • Intravesical
Therapeutic Areas
  • Oncology
Key Developers
  • Sponsor Company: Merck & Co
  • Originator: Virotarg
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.